Answers are grounded in this paper and cite their sources.
Clinical trials of direct oral anticoagulants (DOAC) are scarce and inconclusive in patients who are receiving dialysis, for whom DOAC are not labelled in Europe. In a French nationwide registry study of patients on chronic dialysis, we compared the effectiveness and safety of off-label DOAC use vs approved vitamin K antagonist (VKA).
No takes yet. Share an insight, caveat, or question.
Laville et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: